Expert Insights

Henrik Grönberg, MD, PhD, shared results from the phase 3 ProBio trial which found that androgen receptor pathway inhibitors improved survival outcomes compared to both standard of care and taxanes among patients with metastatic...

Aditya Bardia, MD, discusses results from the TROPION-Breast01 trial comparing datopotamab deruxtecan with chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer who have previously...

At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Eric Padron, MD, discusses updates regarding managing and treating chronic myelomonocytic leukemia.

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Amer Zeidan, MBBS, MHS, provided insights into novel treatment updates for patients with high and low-risk MDS.

Anthony Hunter, MD, Emory University, Atlanta, Georgia, explores options and the use of non-JAK-inhibitor regimens for the treatment of patients with myelofibrosis.

Anthony Hunter, MD, discusses the process of selecting and properly using a JAK-inhibitor for the treatment of patients with myelofibrosis.

Tycel Phillips, MD, discusses 2 recent advancements in the treatment landscape of mantle cell lymphoma, including the use of BTK inhibitor pirtobrutinib, and CAR T-cell therapy treatment lisocabtagene maraleucel.

Tycel Phillips, MD, reports updated findings from a phase 1/2 trial examining the efficacy and safety of glofitamab, a BTK inhibitor, among patients with heavily pretreated R/R mantle cell lymphoma.